Abstract: A peptide which is a variant of the human growth hormone-releasing factor. The peptide, containing 23-28 amino acid residues, differs from its native counterpart at least at positions 8, 9, 16, 18, 24, 25, 27, and 28, and is potent in stimulating the release of growth hormone.

Abstract: This invention is in the field of the chemistry of targeting anticancer anthracycline derivatives. More particularly, it concerns doxorubicin (DOX) or its daunosamine modified derivatives (DM-DOX) linked covalently to analogs of peptide hormones such as LH-RH, bombesin and somatostatin. These covalent conjugates are targeted to various tumors bearing receptors for the peptide hormone analogs. The compounds of this invention are represented by General Formula Q.sup.14 --O--R--P wherein Q has the general formula ##STR1## wherein: Q.sup.14 signifies a Q moiety with a side chain at the 14 position, R-- is H or --C(O)--(CH.sub.2).sub.n --C(O)-- and n=0-7, R' is NH.sub.2 or an aromatic, saturated or partially saturated 5 or 6 membered heterocyclic compounds having at least one ring nitrogen and optionally having a butadiene moiety bonded to adjacent carbon atoms of said ring to form a bicyclic system; P is H or a peptide moiety, suitably an LHRH, somatostatin or bombesin analogs. Nevertheless where R' is NH.sub.

Abstract: The invention comprises a foot-operated control for controlling operation of a computer by providing an input to the computer, such as controlling the position and movement of the computer's cursor in response to movement of one or more of an operator's feet.

Abstract: The present invention provides for a method of detecting antipolymer antibodies, and a method for detecting silicone related disease, fibromyalgia, and chronic fatigue syndrome.

Abstract: Synthetic peptides which have the sequence:Q.sup.1 -CO -Ala.sup.2 -Asp.sup.3 -Ala.sup.4 -Ile.sup.5 -Phe.sup.6 -Thr.sup.7 -R.sup.8 -Ser.sup.9 -Tyr.sup.10 -Arg.sup.11 -R.sup.12 -Val.sup.13 -Leu.sup.14 -R.sup.15 -Gln.sup.16 -Leu.sup.17 -Ser.sup.18 -Ala.sup.19 -Arg.sup.20 -R.sup.21 -Leu.sup.22 -Leu.sup.23 -Gln.sup.24 -Asp.sup.25 -Ile.sup.26 -R.sup.27 -R.sup.28 -NH-Q.sup.2wherein Q.sup.1 is an omega or alpha-omega substituted alkyl of the structure: ##STR1## where: ?.phi.! is phenyl; Y is H, --NH.sub.2, CH.sub.3 CONH--or CH.sub.3 NH--; Z is H or CH.sub.3 ; m is 1 or 2; n is 0, 1 or 2; R.sup.8 is Asn, Ser, Gln or Thr; R.sup.12 is Lys or Orn; R.sup.15 is Gly, Ala, or Abu;R.sup.21 is Lys or Orn; R.sup.27 is Met or Nle; R.sup.28 is Ser or Asp; and Q.sup.2 is a lower omega-guanidino-alkyl group having a formula: --(CH.sub.2).sub.p --NH--C(NH.sub.2).dbd.NH wherein p is 2-6, and the pharmaceutically acceptable addition salts thereof with the pharmaceutically acceptable organic or inorganic bases or acids.

Abstract: Novel peptides of the formula A.sub.1 -A.sub.2 -C.sub.1 -C.sub.2 -C.sub.3 -A.sub.5 are disclosed which promote the release of growth hormone when administered to animals. These peptides can be used therapeutically.

Abstract: A method of promoting or inhibiting spermatogenesis, said method comprising administering to a male an effective amount of PACAP, a PACAP agonist, a PACAP antagonist, PC4, a PC4 agonist, or a PC4 antagonist.

Abstract: A linear peptide which is an analog of a naturally occurring, biologically active peptide having an active site and a binding site responsible for the binding of the peptide to a receptor on a target cell, cleavage of a peptide bond in the active site to the naturally occurring peptide being unnecessary for in vivo biological activity, the analog having a non-peptide bond instead of a peptide bond between an amino acid of the active site and an adjacent amino acid, and having the same binding site as the naturally occurring peptide, so that the analog is capable of acting as a competitive inhibitor of the naturally occurring peptide by binding to the receptor and, by virtue of the non-peptide bond, failing to exhibit the in vivo activity of the naturally occurring peptide.

Abstract: Linear peptide analogs of bombesin with modified amino acid residues at various positions. A peptide of a group of bombesin analogs according to this invention contains either a --CH.sub.2 NH.sub.2 -- pseudopeptide bond, a (3S,4S)-4-amino-3-hydroxy- 6-methylheptanoic acid residue, or a (3S,4S)-4-amino-3- hydroxy-5-phenylpentanoic acid residue.

Abstract: A cyclic peptide analog of somatostatin wherein a disulfide bond links the N-terminus residue and the C-terminus residue.

Abstract: Novel peptides of the formula A.sub.1 -A.sub.2 -Ala-Trp-DPhe-A.sub.5 are disclosed which promote the release of growth hormone when administered to animals. These peptides can be used therapeutically.

Abstract: LHRH analogs and congeners with high water solubility have been synthesized. These new analogs had 0%-100% antiovulatory activity at a 0.5 .mu.g dosage and 0%-80% at 0.25 .mu.g. The ED.sub.50 for histamine release was 30.5 .mu.g/ml->300 .mu.g/ml.

Abstract: Linear peptide analogs of somatostatin having the formula: ##STR1## As an example, D-Phe-Phe-Phe-D-Trp-Lys-Thr-Phe-Thr is covered by the above formula (i.e., R.sub.1 is H, R.sub.2 is H, A.sup.1 is D-Phe, A.sup.2 is Phe, A.sup.3 is Phe, A.sup.6 is Thr, A.sup.7 is Phe, A.sup.8 is Thr, and R.sub.3 is NH.sub.2).

Abstract: A process to aid in the diagnosis of silicone related disease in which a correlation between silicone related disease and the presence of antibodies that bind to partially polymerized acrylamide is disclosed.

Abstract: Disclosed are methods and compositions for the diagnosis and treatment of diseases associated with aberrant expression of a somatostatin receptor (e.g., cancer) or with increased production of a factor regulatable by somatostatin (e.g., acromegaly). The compounds of the invention are of the general formulae: ##STR1## wherein P is a somatostatin peptide analog which binds to a somatostatin receptor,Y is D-tyrosine, L-tyrosine, or desamino-tyrosine,n is an integer from 1 to 32, inclusive,each q, independently, is an integer from 1 to 32, inclusive, and each s, independently, is an integer from 1 to 32, inclusive, where q and s can be the same or different, andX is of the formulaD--NH.sub.2 --CH(CH.sub.2).sub.m NH.sub.2 --CO.sub.2 H orL--NH.sub.2 --CH(CH.sub.2).sub.m NH.sub.2 --CO.sub.2 H,wherein m is an integer from 1 to 10, inclusive.

Abstract: A cyclic octapeptide of the formula: ##STR1## wherein: A.sup.1 is D-Nal or D-Trp;A.sup.3 is Phe, F.sub.5 -Phe, or X-Phe wherein X is a halogen, NO.sub.2, CH.sub.3, or OH;A.sup.5 is --NH--CH(Y)--CO-- wherein Y is (CH.sub.2).sub.m --R.sub.4 --N(R.sub.5)(R.sub.6) or (CH.sub.2).sub.n --R.sub.4 --NH--C(R.sub.7)--N(R.sub.5) (R.sub.6);A.sup.6 is the D-- or L-- isomer of Thr, Leu, Ile, Nle, Val, and Abu;A.sup.8 is Nal or Trp;m is 1, 2, or 3;n is 1, 2, 3, 4 or 5;each of R.sub.1 and R.sub.2, independently, is H, E, COE, or COOE wherein E is C.sub.1-12 alkyl, C.sub.2-12 alkenyl, C.sub.2-12 alkynyl, phenyl, naphthyl, C.sub.7-12 phenylalkyl or alkylphenyl, C.sub.8-12 phenylalkenyl or alkenylphenyl, C.sub.8-12 phenylalkynyl or alkynylphenyl, C.sub.11-20 naphthylalkyl or alkylnaphthyl, C.sub.12-20 naphthylalkenyl or alkenylnaphthyl, or C.sub.12-20 naphthylalkynyl or alkynylnaphthyl, provided that when one of R.sub.1 or R.sub.2 is COE or COOE, the other must be H;R.sub.4 is C.sub.6 H.sub.4 or absent;R.sub.7 is .dbd.NR.sub.

Abstract: The present invention relates to methods of inhibiting HIV-mediated cell killing which comprises inhibiting the interaction between the CS3 region and viral gp41 and its receptor on the surface of lymphocytes. The invention provides for methods which employ peptides, peptide derivatives, or antibodies to inhibit the CS3/CS3 receptor interaction. In addition, the invention also relates to the CS3 receptor.The present invention is based in part on the discovery that a CS3 specific cellular receptor is widely distributed on human lymphocytes and forms a 108 kd complex with CS3-HSA peptide conjugate. It was further discovered that CS3 peptide effectively blocks HIV mediated cell infection and killing. Therefore, the present invention provides for methods of treatment and prophylaxis of HIV infection as well as a means for better understanding the physiology of acquired immunodeficiency syndrome (AIDS).

Abstract: Synthetic analogues of hGH-RH(1-29)NH.sub.2 having substitutions of various amino acids and acylated at the N-terminus, and exhibiting prolonged antagonistic duration. Embodiments include analogues of the formula: ##STR1## wherein X is nil, H, Ac, IAc, BrProp, Ibu, Nac, 2-Nac, 1- or 2-Npt, 1- or 2-Npr or Aqc; R.sup.1 is Tyr, His, Glu or Glt; R.sup.2 is D-Arg, D-Cit, D-Har, D-Lys or D-Orn; R.sup.3 is Asp, Ala or Gly; R.sup.4 is Ala or Gly; R.sup.5 is Ile, Ala or Gly; R.sup.6 is Phe, Ala, Pro, Tpi, Nal or Phe(Y), in which Y is F, Cl, Br, NO.sub.2, CH.sub.3 or OCH.sub.3 ; R.sup.8 is Asn, Ser, Val, Ile, Ala, Abu, Nle, or Aib; R.sup.11 is Arg, D-Arg or Cit; R.sup.12 is Lys, D-Lys, Cit or Ala; R.sup.15 is Gly, Ala, Abu or Gln; R.sup.19 is Ala or Abu; R.sup.20 is Arg, D-Arg or Cit; R.sup.21 is Lys, D-Lys or Cit; R.sup.27 is Met, Nle or Abu; R.sup.28 is Ser, Asn, Asp or Abu; R.sup.29 is Agm, Arg-NH.sub.2, Arg-OH, Cit-NH.sub.2, Cit-OH, Har-NH.sub.2 or Har-OH; provided that when R.sup.

Abstract: A compound of the formula: ##STR1## wherein each A.sub.1 and A.sub.2, independently, is H, C.sub.1-12 alkyl, C.sub.7-10 phenylalkyl, R.sub.1 CO (where R.sub.1 is C.sub.1-20 alkyl, C.sub.3-20 alkenyl, C.sub.3-20 alkinyl, phenyl, naphthyl, or C.sub.7-10 phenylalkyl), or R.sub.2 OCO (where R.sub.2 is C.sub.1-10 alkyl or C.sub.7-10 phenylalkyl), provided that when one of A.sub.1 or A.sub.2 is R.sub.1 CO or R.sub.2 OCO, the other must be H;each X.sub.1 and X.sub.2, independently, is H, F, Cl, Br, OH, CH.sub.3, or CF.sub.3, provided that at least one of X.sub.1 and X.sub.2 must be H;A.sub.3 is Phe or Tyr; andA.sub.4 is OH, NH.sub.2, or NH-R.sub.3 (wherein R.sub.3 is a saturated aliphatic C.sub.1-8 alkyl);or a pharmaceutically acceptable salt thereof. A therapeutic composition containing the compound of the present invention and a method of using the same are also described.

Abstract: An apparatus and method for fabricating directional fiber optic taps having a variety of output angles. The taps can be used to monitor losses due to misalignment of the fiber or losses due to bending and straining of the fiber. The apparatus and method can also be used to fabricate taps which filter out higher order modes in a fiber. The apparatus and method can also be used to produce taps which can be used in a position or refractive index measuring system.